Drug Approval | June 26, 2024
USDA approves Merck Animal Health’s NOBIVAC NXT canine flu H3N2
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
The facility was inspected from May 7 to May 17, 2024
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Renews GMP certifications for India and Malaysia sites
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Subscribe To Our Newsletter & Stay Updated
